This is a protocol for expanded access use of nogapendekin-alfa inbakicept (N-803/NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are ineligible to participate in a clinical...
This is a phase II, randomized, unblinded, controlled trial to investigate the safety, tolerability and immunomodulation effect of combining N-803 with antiretroviral therapy (ART) during acute HIV infection (AHI). The study will be conducted at one study site, the...
This Phase 1 randomized “HIV Cure Study” is evaluating whether ImmunityBio’s investigational agent N-803 along or together with broadly neutralizing antibodies can control HIV following antiretroviral therapy.
